


#10
GP 16247 2/21/02
§3W

Attorney Docket No.: 5390.200-US

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dörwald et al.

Serial No.: 09/548,081 ✓

Group Art Unit: 1624

Filed: April 12, 2000 ✓

Examiner: H. Liu

Confirmation No: 5691

For: Substituted Imidazoles, their Preparation and Use ✓

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Second Supplemental Information Disclosure Statement (in duplicate)
2. Form PTO-1449
3. Copy of Reference

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on December 19, 2001.

COPY OF PAPERS
ORIGINALLY FILED

Carol McFarlane-Fishberg
(name of person mailing paper)

Carol McFarlane-Fishberg ✓
(signature of person mailing paper)



23650

PATENT TRADEMARK OFFICE

#10

Attorney Docket No.: 5390.200-US

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dörwald et al.

Application No.: 09/548,081

Group Art Unit: 1624

Filed: April 12, 2000

Examiner: H. Liu

Confirmation No: 5691

RECEIVED

FEB 04 2002

TECH CENTER 1600/2900

For: Substituted Imidazoles, their Preparation and Use

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith a reference which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the reference may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that this reference is "prior art" unless specifically designated as such.

The filing of this Second Supplemental Information Disclosure Statement shall not be construed as a representation that no other material references than this listed exists or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the reference is also enclosed.

The reference is as follows:

1. EP 0 458 661 A1.

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached reference.

01/28/2002 MWOLDER1 00000328 141447 09548081


01 FC:126 180.00 CH

This second supplemental information disclosure statement is being filed after the period set forth in 37 C.F.R. 1.97(b), but before the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this second supplemental information disclosure statement is the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Date: December 19, 2001

Respectfully submitted,



Peter J. Waibel, Reg. No. 43,228
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE